Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • AZD3463 ALK/IGF1R Inhibitor: Mechanisms, Evidence, and In...

    2025-10-29

    AZD3463 ALK/IGF1R Inhibitor: Mechanisms, Evidence, and Integration

    Executive Summary: AZD3463 is a small molecule inhibitor with high affinity for ALK and IGF1R (Ki = 0.75 nM), showing efficacy in neuroblastoma models with wild type and mutant ALK (F1174L, D1091N) (AZD3463 product page). It suppresses neuroblastoma cell proliferation by targeting the ALK-mediated PI3K/AKT/mTOR pathway, leading to apoptosis and autophagy induction (Labrèche et al. 2021). AZD3463 demonstrates dose-dependent in vitro activity (5–50 μM) and synergizes with chemotherapeutics such as doxorubicin and temozolomide. In vivo, it significantly reduces tumor growth in orthotopic neuroblastoma xenografts at 15 mg/kg via intraperitoneal injection. Proper solubilization and storage are critical for experimental reproducibility (A8620 kit).

    Biological Rationale

    Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase expressed predominantly in neurons and upregulated in neuroblastoma (Labrèche et al., 2021). ALK activation promotes cell survival and proliferation via the PI3K/AKT/mTOR pathway. Mutations such as F1174L and D1091N in ALK drive tumorigenesis and confer resistance to first-generation ALK inhibitors. IGF1R signaling also contributes to oncogenic survival signaling and interacts with PI3K/AKT axis. Targeting these pathways is critical for overcoming therapy resistance in ALK-driven cancers. AZD3463 was developed to inhibit both ALK and IGF1R efficiently, with a molecular weight of 448.95 and chemical formula C24H25ClN6O (AZD3463 ALK/IGF1R inhibitor).

    Mechanism of Action of AZD3463 ALK/IGF1R inhibitor

    AZD3463 selectively inhibits ALK and IGF1R kinase activity by occupying the ATP-binding site. This blocks downstream phosphorylation events, suppressing the PI3K/AKT/mTOR signaling cascade. Inhibition of this pathway reduces expression of survival and proliferation genes and induces apoptosis and autophagy in neuroblastoma cells (Labrèche et al. 2021). In cellular models, AZD3463 disrupts signal transduction even in the presence of activating ALK mutations (F1174L, D1091N), which are known to confer resistance to crizotinib and related inhibitors. The compound’s dual inhibition prevents compensatory signaling via IGF1R, enhancing its cytotoxic effect. The result is a robust suppression of tumor cell growth, confirmed by dose-dependent cytotoxicity assays (5–50 μM range). Combination with chemotherapeutic agents like doxorubicin or temozolomide increases efficacy by synergistically promoting apoptosis (CASPBio overview—this article provides deeper mechanistic details and updated in vivo data).

    Evidence & Benchmarks

    • AZD3463 exhibits high ALK inhibitory potency (Ki = 0.75 nM) under standardized biochemical assay conditions (product data).
    • In vitro, AZD3463 suppresses proliferation of neuroblastoma cell lines with wild type or F1174L/D1091N mutant ALK at concentrations of 5–50 μM (cell viability, 72 h, DMSO vehicle control) (Labrèche et al. 2021).
    • AZD3463 induces apoptosis and autophagy markers (elevated caspase-3/7 activity, increased LC3-II) in treated neuroblastoma cells (dose: 20 μM, 24–48 h) (Labrèche et al. 2021).
    • Combination treatment with doxorubicin or temozolomide enhances cytotoxicity (synergistic effect, combination index <1) in resistant neuroblastoma models (product sheet).
    • In vivo, daily intraperitoneal AZD3463 (15 mg/kg, 2 days) significantly reduces tumor volume in orthotopic neuroblastoma xenografts (n = 6, p < 0.05 vs. control) (Labrèche et al. 2021).
    • AZD3463 overcomes resistance to crizotinib by targeting activating ALK mutations not addressed by first-generation inhibitors (ALK-1 resource; this article updates the cross-resistance landscape and provides new combinatorial data).

    Applications, Limits & Misconceptions

    AZD3463 is optimized for research on ALK-driven neuroblastoma and other IGF1R/ALK-dependent malignancies. It is particularly valuable in studies of resistance mechanisms, signaling pathway crosstalk, and combination regimens. For a comprehensive view of translational applications and clinical strategies, see the thought-leadership article Next-Generation ALK Inhibition in Neuroblastoma—the present article clarifies the in vitro/in vivo quantitative benchmarks and provides updated workflow integration instructions.

    Common Pitfalls or Misconceptions

    • Not a pan-kinase inhibitor: AZD3463 is selective for ALK and IGF1R; it does not broadly inhibit unrelated kinases.
    • Solubility limitations: The compound is insoluble in water and ethanol; DMSO is required for stock preparation at ≥11.22 mg/mL.
    • No long-term DMSO solution storage: Working solutions should be prepared fresh or stored at -20°C for a few months. Longer storage may compromise activity.
    • Not a substitute for clinical ALK inhibitors: AZD3463 is intended for research use only and is not approved for therapeutic administration to humans.
    • Resistance outside ALK/IGF1R axis: Tumors driven by alternative pathways may not respond to AZD3463.

    Workflow Integration & Parameters

    For experimental use, AZD3463 (A8620) should be dissolved in DMSO and warmed or sonicated to enhance solubility. Typical working concentrations for in vitro studies range from 5 to 50 μM. For in vivo mouse models, daily intraperitoneal dosing at 15 mg/kg for 2 days has been validated. Store lyophilized powder at -20°C and protect DMSO solutions from light and repeated freeze-thaw cycles. For more on structural insights and future research strategies, see AZD3463: Structural Insights and Future Applications—this article provides parameterization and best practices not previously detailed.

    Conclusion & Outlook

    AZD3463 is a well-validated tool for dissecting ALK/IGF1R signaling, overcoming resistance mutations, and enabling combination therapy research in neuroblastoma. Its high selectivity and robust in vivo activity distinguish it from earlier inhibitors. Continued integration into translational cancer models, with careful attention to solubility and storage, will advance understanding of ALK-driven oncogenesis and inform next-generation therapeutic strategies.